Meeting
2015 ASCO Annual Meeting
A randomized, phase III study (FLAURA) of AZD9291, a novel EGFR-TKI, versus gefitinib or erlotinib in treatment-naïve patients with advanced non-small cell lung cancer and an EGFR-TKI-sensitizing mutation.
Authors
Suresh S. Ramalingam
The Winship Cancer Institute of Emory University, Atlanta, GA
Suresh S. Ramalingam , Yuri Rukazenkov , Karen Thomas , Jean-Charles Soria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02296125
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS8102)
DOI
10.1200/jco.2015.33.15_suppl.tps8102
Abstract #
TPS8102
Poster Bd #
427a
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Real-world (RW) outcomes for advanced non-small cell lung cancer (aNSCLC) patients (pts) with EGFR exon 19 deletions (x19del) stratified by deletion size.
First Author: Sai-Hong Ignatius Ou
Poster
2019 ASCO Annual Meeting
Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial.
First Author: Caicun Zhou
Poster
2023 ASCO Quality Care Symposium
Stepwise prolongation of overall survival from first- to third-generation EGFR-tyrosine kinase inhibitors in non-small cell lung cancer and the prognostic impact of concomitant antacids.
First Author: Kiyoaki Uryu
Poster
2023 ASCO Annual Meeting
Osimertinib then chemotherapy in EGFR-mutated lung cancer with osimertinib third-line rechallenge (OCELOT).
First Author: Daniel Adam Breadner